The animal origin-free (AOF) trend in bioprocessing has taken a while to reach microbial bioproduction. In this podcast, we explore the reasons behind this and delve into how AOF products are impacting the future of biopharmaceutical manufacturing. We also discuss the first chemically defined microbial medium—the Gibco™ Bacto™ CD Supreme Fermentation Production Medium (FPM). Hydrolysate-free and AOF, this dry powder medium was specially designed to support high-cell-density cultures of E. Coli. Listen to bioprocessing experts and discover more.
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Nate Edwards of Arya Consulting, Elisabeth Gardiner of Tevard Biosciences, and Donny Xu of the RTW Institute discuss global competition for rare disease therapies.
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.